Lioresal (Baclofen)

Baclofen acts as an agonist at GABA_B receptors located primarily in the dorsal horn of the spinal cord. Activation of these receptors inhibits the release of excitatory neurotransmitters, reduces neuronal firing, and dampens reflex pathways that contribute to heightened muscle tone. This mechanism results in decreased spasticity and improved motor control.

The dose of intrathecal baclofen is individualized by the prescribing physician based on the severity of spasticity, patient weight, and response to therapy. Dosing typically begins with a low initial volume delivered via an implanted pump and is titrated upward in small increments under clinical supervision. Exact dosing regimens should be obtained from the treating neurologist or physiatrist.

Safety data for intrathecal baclofen during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is generally reserved for situations where the potential benefit to the mother outweighs possible risks to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative therapies when appropriate.

To request Lioresal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Compared with oral baclofen, the intrathecal formulation delivers medication directly to the central nervous system, allowing lower total doses and often fewer systemic side effects such as drowsiness. Other agents like tizanidine or diazepam act through different mechanisms and may cause more sedation or hypotension. Choice of therapy depends on the severity of spasticity, patient tolerance, and the feasibility of pump implantation.

Lioresal intrathecal solution should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and freezing temperatures. Before use, inspect the vial for any particulate matter or discoloration, and handle it with aseptic technique to maintain sterility for intrathecal administration.

Lioresal is administered via an implanted intrathecal pump that delivers a controlled volume of baclofen directly into the cerebrospinal fluid. The pump is surgically placed in the abdominal wall, with a catheter extending to the intrathecal space. Dosing is programmed by a qualified clinician, and the pump may be refilled percutaneously in an outpatient setting according to the prescribed schedule.

Serious adverse events include respiratory depression, seizures, and severe allergic reactions such as anaphylaxis. Abrupt discontinuation of intrathecal baclofen can lead to withdrawal syndrome, characterized by high fever, altered mental status, and rebound spasticity, which may be life‑threatening. Patients should be monitored closely for these signs, and any sudden changes in therapy should be managed by a healthcare professional.

Lioresal is contraindicated in individuals with known hypersensitivity to baclofen or any component of the formulation. It should also be avoided in patients with active infection at the pump implantation site, uncontrolled epilepsy, or severe respiratory insufficiency. Patients with certain cardiac conditions or those taking interacting central nervous system depressants should be evaluated carefully before initiating therapy.